We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Revitope will leverage its proprietary protein engineering platform together with Junshi's novel antibody components to develop first-in-class dual-antigen targeting cancer therapies.